Search for content, post, videos

InDex Pharmaceuticals receives FDA clearance

Peter Zerhouni Photo Kristian Pohl

The U.S. Food and Drug Administration (FDA) has given clearance to start the company’s phase III clinical study CONCLUDE in the United States.

The study will evaluate the efficacy and safety of the TLR9 agonist cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.

“The United States is the largest pharmaceutical market in the world, and to receive clearance from the FDA  to start the phase III study CONCLUDE with cobitolimod is an important milestone for InDex,” says Peter Zerhouni, CEO of InDex Pharmaceuticals.

Read more: Hey there Peter Zerhouni, CEO, InDex Pharmaceuticals

CONCLUDE

CONCLUDE is a global phase III study that will be conducted at several hundred clinics in over 30 countries. The process of applying for and obtaining approval from the relevant authorities in the participating countries is ongoing. It is a randomized, double-blind, placebo-controlled, clinical study to evaluate cobitolimod as a novel treatment for patients with moderate to severe left-sided ulcerative colitis.

The induction study will include approximately 440 patients, and the primary endpoint will be clinical remission at week 6. Apart from the dosing 250 mg x 2, which was the highest dose and the one that showed the best efficacy in the phase IIb study CONDUCT, the phase III study will also evaluate a higher dose, 500 mg x 2, in an adaptive study design. Patients responding to cobitolimod in the induction study will be eligible to continue in a one-year maintenance study, where they will be treated with either cobitolimod or placebo.

Photo of Peter Zerhouni: Kristian Pohl